LIGANDOLIPOSOME BASED GENE DELIVERY FOR CANCER THERAPY

Information

  • Research Project
  • 2872030
  • ApplicationId
    2872030
  • Core Project Number
    R43CA082045
  • Full Project Number
    1R43CA082045-01
  • Serial Number
    82045
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/20/1999 - 25 years ago
  • Project End Date
    12/31/1999 - 25 years ago
  • Program Officer Name
    FU, YALI
  • Budget Start Date
    4/20/1999 - 25 years ago
  • Budget End Date
    12/31/1999 - 25 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/20/1999 - 25 years ago
Organizations

LIGANDOLIPOSOME BASED GENE DELIVERY FOR CANCER THERAPY

DESCRIPTION: (adapted from applicant's abstract) Development of an effective vehicle for cancer gene therapy using novel multigenic vectors is proposed. Liposomes are safe and promising nonviral vehicles for gene therapy. However, their use is limited by specificity. The goal of this proposal is to develop novel targeted liposome-based delivery vehicles for the above vectors. Focusing on the EGF family of receptors which are frequently overexpressed in cancers of epithelial origin, natural ligands will be attached to a common phospholipid component of cationic liposomes and the ability tested of these ligands to specifically direct the liposome carrier to breast cancer cell lines. Transfection efficiency of different liposome mixtures will be tested. In subsequent phases, the most efficient system will be selected for in vivo studies. The ultimate goal is to develop targeted ligand-linked liposomes for systemic administration of therapeutic genes into cancer patients. PROPOSED COMMERCIAL APPLICATION: The proposed research will lead to the development of targeted nonviral gene delivery vehicles to overcome a major barrier to in vivo gene delivery which is lack of specificity. The commercial applications are widespread, ranging from gene therapy, particularly in cancer, as well as in any basic research procedure that requires in vivo transfection to specific cell types.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    INVIVOGEN CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921211420
  • Organization District
    UNITED STATES